ProKidney Corp. Market Cap ($222.51 Million)
Market Cap & Net Worth: ProKidney Corp. (PROK)
ProKidney Corp. market cap. ProKidney Corp. (NASDAQ:PROK) has a market capitalization of $222.51 Million ($222.51 Million) as of November 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15924 globally and #3794 in its home market, demonstrating a -29.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ProKidney Corp.'s stock price $1.07 by its total outstanding shares 208926941 (208.93 Million). Also see PROK cash flow conversion for how efficiently the company converts equity into cash flow.
ProKidney Corp. Market Cap History (2021–2026)
ProKidney Corp. market cap history from 2021 to 2026. Data shows change from $2.07 Billion to $222.51 Million (-34.32% CAGR). Check ProKidney Corp. (PROK) stock price for real-time trading data and today's change.
Index Memberships
ProKidney Corp. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.01% | #424 of 976 |
|
NASDAQ Composite
IXIC
|
$38.55 Trillion | 0.00% | #1553 of 3165 |
Weight: ProKidney Corp.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ProKidney Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ProKidney Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PROK net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
524.07x
ProKidney Corp.'s market cap is 524.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $353.09 Million | $76.00K | -$61.19 Million | 4645.88x | N/A |
| 2025 | $468.00 Million | $893.00K | -$68.99 Million | 524.07x | N/A |
Competitor Companies of PROK by Market Capitalization
Companies near ProKidney Corp. in the global market cap rankings as of November 7, 2026. Also see ProKidney Corp. total assets for a full breakdown of the balance sheet.
Key companies related to ProKidney Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of ProKidney Corp. (2021–2026)
Market capitalization of ProKidney Corp. from 2021 to today. Between 2021 and today, ProKidney Corp.'s market cap moved from $2.07 Billion to $ 222.51 Million, with a yearly change of -34.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $222.51 Million | -52.46% |
| 2025 | $468.00 Million | +32.54% |
| 2024 | $353.09 Million | -5.06% |
| 2023 | $371.89 Million | -74.05% |
| 2022 | $1.43 Billion | -30.71% |
| 2021 | $2.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of ProKidney Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $222.51 Million USD |
| MoneyControl | $222.51 Million USD |
| MarketWatch | $222.51 Million USD |
| marketcap.company | $222.51 Million USD |
| Reuters | $222.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more